Evidence map›Paper›PMID 40547414›Full record

ArticleSAGE open medical case reports2025

Upadacitinib in refractory cutaneous pseudolymphoma: A case report.

Elisabetta Danese, Tea Curic, Francesco Bellinato, Chiara Colato, Paolo Gisondi, Giampiero Girolomoni

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisabetta DaneseSection of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.ORCID https://orcid.org/0009-0003-9793-6998
Tea CuricSection of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.
Francesco BellinatoSection of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.
Chiara ColatoSection of Pathology, Department of Diagnostics and Public Health, University of Verona, Italy.
Paolo GisondiSection of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.ORCID https://orcid.org/0000-0002-1777-9001
Giampiero GirolomoniSection of Dermatology and Venereology, Department of Medicine, University of Verona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous pseudolymphoma is a benign condition characterized by a reactive B-cell, T-cell or mixed lymphoproliferative process. Different causative agents (e.g. injected substances, tattoo, drugs and insect bites) have been described, but in many cases no cause can be identified; hence, the term idiopathic cutaneous pseudolymphoma. There are no specific guidelines for the treatment of cutaneous pseudolymphoma, and sometimes a few cases are refractory to conventional treatments. We describe a case of a 41-year-old African woman with refractory facial IgG4 pseudolymphoma successfully treated with upadacitinib.

Indexed as

cutaneous pseudolymphomaJAK inhibitorsupadacitinib

Identifiers

PMID40547414
PMCPMC12179454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.